Abstract:Background: Endogenous insulin supplementation is essential for individuals with type 1 diabetes (T1D). However, current treatments, including pancreas transplantation, insulin injections, and oral medications, have significant limitations. The development of engineered cells that can secrete endogenous insulin offers a promising new therapeutic strategy for type 1 diabetes (T1D). This approach could potentially circumvent autoimmune responses associated with the transplantation of differentiated β-cells or systemic delivery of viral vectors. Methods: We utilized CRISPR/Cas9 gene editing coupled with homology-directed repair (HDR) to precisely integrate a promoter-free EMCVIRES-insulin cassette into the 3' untranslated region (UTR) of the GAPDH gene in human HEK-293T cells. Subsequently quantified insulin expression levels in these engineered cells, the viability and functionality of the engineered cells when seeded on different cell vectors (GelMA and Cytopore I) were also assessed. Finally, we investigated the therapeutic potential of EMCVIRES-based insulin secretion circuits in reversing Hyperglycaemia in T1D mice. Result: Our results demonstrate that HDR-mediated gene editing successfully integrated the IRES-insulin loop into the genome of HEK-293T cells, a non-endocrine cell line, enabling the expression of human-derived insulin. Furthermore, Cytopore I microcarriers facilitated cell attachment and proliferation during in vitro culture and enhanced cell survival post-transplantation. Transplantation of these cell-laden microcarriers into mice led to the development of a stable, fat-encapsulated structure. This structure exhibited the expression of the platelet-endothelial cell adhesion molecule CD31, and no significant immune rejection was observed throughout the experiment. Diabetic mice that received the cell carriers reversed hyperglycemia, and blood glucose fluctuations under simulated feeding stimuli were very similar to those of healthy mice. Conclusion: In summary, our study demonstrates that Cytopore I microcarriers are biocompatible and promote long-term cell survival in vivo. The promoter-free EMCVIRES-insulin loop enables non-endocrine cells to secrete mature insulin, leading to a rapid reduction in glucose levels. We have presented a novel promoter-free genetic engineering strategy for insulin secretion and proposed an efficient cell transplantation method. Our findings suggest the potential to expand the range of cell sources available for the treatment of diabetes, offering new avenues for therapeutic interventions.

Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes

Oral Delivery of Single-Chain Insulin (SCI-59) Analog by Bacterium-Like Particles (blps) Induces Oral Tolerance and Prevents Autoimmune Diabetes in NOD Mice.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

In Vivo Targeted Delivery of ANGPTL8 Gene for Beta Cell Regeneration in Rats

Successful Β Cells Islet Regeneration Instreptozotocin-Induced Diabetic Baboons Usingultrasound-Targeted Microbubble Gene Therapywith Cyclind2/cdk4/glp1

A engineered Bifidobacterium longum secreting a bioative penetratin-Glucagon-like peptide 1 fusion protein enhances Glucagon-like peptide 1 absorption in the intestine.

Biochemotaxis-Oriented Engineering Bacteria Expressing GLP-1 Enhance Diabetes Therapy by Regulating the Balance of Immune

Reversal of Streptozotocin-Induced Diabetes in Rats by Gene Therapy with Betacellulin and Pancreatic Duodenal Homeobox-1

Diabetes treatment by conversion of gut epithelial cells to insulin‐producing cells

Modulation of Intestinal and Systemic Inflammation by Liraglutide and Lactobacillus Plantarum Ameliorates Intestinal Dysfunction and Glucolipid Abnormalities in Diabetic Rats

Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice

Oral Route Of Mini-Proinsulin-Expressing Ganoderma Lucidum Decreases Blood Glucose Level In Streptozocin-Induced Diabetic Rats

Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia

Attenuation of Hyperglycemia in Diabetic Rats Assisted by Immobilized Probiotic in Sodium Alginate

Garlic Extract Promotes Pancreatic Islet Neogenesis Through α-to-β-Cell Transdifferentiation and Normalizes Glucose Homeostasis in Diabetic Rats

Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control

Glucagon Receptor Antagonism Promotes the Production of Gut Proglucagon-Derived Peptides in Diabetic Mice.

Angiotensin-(1–7) Expressed From Lactobacillus Bacteria Protect Diabetic Retina in Mice

Improvement effect of a next-generation probiotic L. plantarum-pMG36e-GLP-1 on type 2 diabetes mellitus via the gut-pancreas-liver axis.

Control of insulin secretion by GLP-1